China Pharma Univ. IDO2 compound 22

China Pharma Univ. IDO2 compound 22: sourced facts only. name: "Our study offered for the first time a selective small-molecule IDO2 inhibitor 22 with IC50 at the nanomolar level, which may be used not only as a candidate compound for the treatment of autoimmune diseases but also as a tool compound for further IDO2-related mechanistic study." [PMID:35952367]; target: "Our study offered for the first time a selective small-molecule IDO2 inhibitor 22 with IC50 at the nanomolar level, which may be used not only as a candidate compound for the treatment of autoimmune diseases but also as a tool compound for further IDO2-related mechanistic study." [PMID:35952367]; developer: "State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China." [PMID:35952367]; modality: "Our study offered for the first time a selective small-molecule IDO2 inhibitor 22 with IC50 at the nanomolar level, which may be used not only as a candidate compound for the treatment of autoimmune diseases but also as a tool compound for further IDO2-related mechanistic study." [PMID:35952367]; stage: "Notably, treatment with 22 alleviated disease severity and reduced inflammatory cytokines in both the collagen-induced arthritis (CIA) mice model and adjuvant arthritis (AA) rat model." [PMID:35952367]